AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02318498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CMR
Description: Intervention performed 2-4 days after admission to hospital with the latest CMR technique including sensitive oedema sequences using T1 mapping
Study NCT02315898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment-inhaled tPA
Description: Enrolled patients with acute plastic bronchitis (fibrin airway casts) will receive inhaled tPA treatment. The tPA regimen will consist of 5mg every six hours for a total of 72 hours.
Study NCT02641613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retroclavicular block
Description: retroclavicular block for forearm or hand surgery
Study NCT02641613 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular block
Description: supraclavicular block for forearm or hand surgery
Study NCT02064426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: Subjects will continue with the same treatment they were receiving in the parent study (16208). BAY85-3934 will be administered daily as oral tablets. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits, the dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose. Total treatment time is up to 36 months. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
Study NCT02064426 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa/beta
Description: Subjects will continue with the same treatment they were receiving in the parent study (16208). Epoetin alfa / beta will be administered as intravenous (IV) or subcutaneous (SC) injections per individual subject regimen according to the local label. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits,dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose.Total treatment time is up to 36 months.
Study NCT04020107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compressive garment and Somatosensori Remediation
Description: Each patient will benefit successively: from a classic care, over a period of 2 to 4 months, then will be treated with compressive or low compressive garments associated with specific proprioceptive physiotherapy program during the next 4 months. Finally, the 4 last months, patient will made adapted physical activity with both dance sessions strengthening the body diagram and stretching sessions
Study NCT04020107 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Compressive garment and Somatosensori Remediation
Description: Each patient will benefit successively: from a classic care, over a period of 2 to 4 months, then will be treated with compressive or low compressive garments associated with specific proprioceptive physiotherapy program during the next 4 months. Finally, the 4 last months, patient will made adapted physical activity with both dance sessions strengthening the body diagram and stretching sessions
Study NCT00523393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargin
Description: Titration of bedtime insulin glargin aiming at normal morning fasting glucose
Study NCT00523393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Insulin
Description: Titration of bedtime human insulin aiming at normal morning fasting glucose
Study NCT02330120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Study NCT02330120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Study NCT00017563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 35 mg/m2 i.v. over 15 - 30 minutes will be administered immediately after the mitoxantrone on the same schedule.
Study NCT00017563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Initial dose will be 2 mg/m2 weekly for 3 of every 4 weeks. The dose will then be escalated as described in the dose escalation section up to a maximum dose of 6 mg/m2 weekly for 3 of every 4 weeks.
Study NCT00017563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Prostatectomy will be scheduled 2 - 4 weeks after the last dose of chemotherapy.
Study NCT02352337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX
Description: Perfusion :oxaliplatine, Irinotecan ,folinic acid, 5FU bolus and continue
Study NCT02352337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Perfusion :oxaliplatine, Irinotecan ,folinic acid, 5FU bolus and continue
Study NCT02352337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2
Description: Perfusion: Folinic Acid,5FU Bolus,5FU continue
Study NCT02352337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI.3
Description: Perfusion :Irinotecan,Acide folinique ,5FU continue
Study NCT02352337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine perfusion
Study NCT01230151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GUIDE software, Version 0.1
Description: The GUIDE software uses computer-based models to determine the spread of stimulation from DBS therapy into surrounding nuclei of the brain. The software models stimulation and is not used to program or communicate with the patient's implanted DBS System. The software was recently validated in a multi-center clinical study.
Study NCT01230151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clinically defined stimulation parameters
Description: Stimulation parameters clinically determined prior to start of clinical study
Study NCT01433835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-400
Description: Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
Study NCT01433835 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
Study NCT00365261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone
Description: eszopiclone 2 to 3 mg po at bedtime
Study NCT00365261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 2 to 3 mg po at bedtime
Study NCT04480463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCD411
Description: IVT (intravitreal) injection
Study NCT04480463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: IVT injection
Study NCT02026414 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PrimaVie
Description: Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
Study NCT02026414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT00071552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qvar
Description: Qvar (HFA-propelled beclomethasone dipropionate metered dose inhaler) 160 mcg twice daily for 12 weeks
Study NCT04111536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liothyronine
Description: Each treatment period of liothyronine was approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo.
Study NCT04111536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: liothyronine
Description: Each treatment period of liothyronine was approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo.
Study NCT04111536 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Each treatment period of placebo was approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - LT3.
Study NCT04111536 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each treatment period of placebo was approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - LT3.
Study NCT01348750 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healing Touch & Guided Imagery
Description: Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and the energy centers which control the flow of energy to the physical body.~HT complements traditional health care and is used together with other approaches to health and healing.~Guided Imagery (GI) is a form of focused relaxation used to create harmony between the mind and body. Positive mental imagery can promote relaxation, reduce stress and improve mood as well as alter heart rate, blood pressure and breathing.
Study NCT04375384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: A loading dose of Cetuximab will be administered intravenously in the first day of treatment. The dose is 400 mg/m2 and will be infused over 2h followed by 1h observation.~The maintenance dose of Cetuximab is 250 mg/m2 and will be infused over 1h. No further observation time needed.~The maintenance dose of cetuximab will be given every 7 days (+/- 2 days) starting 7 days (+/- 2 days) after the loading dose of cetuximab.~Pre-medicate with 50 mg Diphenhydramine IV before the loading dose of Cetuximab and as per standard of care before the maintenance treatment.
Study NCT04375384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study NCT00071552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flovent Diskus
Description: Flovent Diskus (fluticasone propionate multi-dose dry powder inhaler) 200 mcg twice daily for 12 weeks
Study NCT00408733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Education Tool
Description: Picture and Icon-based Customizable Educational Tool
Study NCT03453177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care + Fosfomycin
Description: Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).
Study NCT04375384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Description: Ancillary studies
Study NCT03758989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Prednisone
Description: A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
Study NCT03758989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
Study NCT03758989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
Study NCT03453177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PK
Description: Two PK samples will be taken after each of the first IV and oral doses, with sampling times allocated within possible early (5, 10 or 60 minutes) and late (2, 4 or 8 hours) time-points after starting the IV and PO formulations; then again together with biochemistry after 7 days for those babies whom remain as inpatients.
Study NCT03453177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Analysis of Bacterial Isolates
Description: For assessment of susceptibility patterns in bowel flora, we will systematically assess all admission and discharge nappy swabs.
Study NCT00990821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes
Study NCT03758989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
Study NCT00990821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
Study NCT05411042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dance somatosensory game
Description: dance somatosensory game (DSG), DANZ BASE developed by International Games System Company
Study NCT02022813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplemental parenteral nutrition (SPN)
Description: The amount of energy delivered by SPN will depend on the indirect calorimetry measurement and actual enteral feed delivery. SPN will be reduced with progressing EN
Study NCT01844583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib tablets
Study NCT01844583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole capsules
Study NCT01844583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin capsules
Study NCT03757962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Limiting dietary exposure to benzoic acid, sorbic acid, polysorbates and related food additives; limiting eating out to a maximum of 2 days per week.
Study NCT01032395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Focetria®
Description: 7.5 ug of HA antigen; adjuvanted; monovalent
Study NCT01032395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluad®
Description: 15 ug of HA antigen; adjuvanted; trivalent
Study NCT01032395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Begrivac®
Description: 15 ug of antigen; non-adjuvanted; trivalent
Study NCT03761836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShangRing
Description: The ShangRing™ is a device for male circumcision that was invented by Jian Zhong Shang and has been on the Chinese market since 2005. It consists of a sterile device with two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. It currently holds a European Conformity (CE) mark, an EN ISO certificate, and is FDA approved. Clinical data from ShangRing studies in Africa were reviewed by the WHO Technical Advisory Group (TAG) on Innovations in Male Circumcision in January 2013 and were found to meet its clinical requirements. The ShangRing manufacturer was accepted by the WHO Prequalification Programme for Male Circumcision Devices in 2015.
Study NCT02741492 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plane Block
Description: Continuous Nerve Block
Study NCT02741492 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Block
Description: Continuous Sham Catheter
Study NCT01973114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Study NCT03758989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
Study NCT01973114 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03316313 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatitis C Antibody
Description: Patients who received a blood test to screen for the Hepatitis C virus.
Study NCT01468051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: four doses of Euvax B vaccine
Description: 40 μg (2 ml) four doses of Euvax B vaccine
Study NCT01468051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 μg (1 ml) three doses of Euvax B vaccine
Description: 20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
Study NCT02007148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: twice a day
Study NCT02007148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: cycles repeated every 3 weeks
Study NCT03804320 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active Surveillance
Study NCT04568447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMOOVE
Description: Imoove® is a device dedicated to rehabilitation and fitness and has the capacity to increase muscle tenfold.
Study NCT00992264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Tone
Description: All participants receive an tailored, online smoking cessation program. Participants in this intervention group either receive content written in a prescriptive tone or a motivational tone.
Study NCT00992264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation
Description: Persons in this arm either have their ability to navigate the site dictated for them based on their readiness to quit smoking or they are able to freely navigate through the website.
Study NCT00992264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Outreach
Description: Persons receive periodic, proactively delivered email reminders to visit the intervention website.
Study NCT00992264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Testimonials
Description: People receive a personally-tailored testimonial as part of their online smoking cessation program.
Study NCT04106375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online mindfulness based cognitive therapy intervention
Description: MBCT is based on Mindfulness-Based Stress Reduction (MBSR), combining principles of cognitive therapy (CT) with those of mindfulness meditation to prevent depression relapse. Both MBSR and MBCT use contemplative practices, including sitting meditation, body scan and walking meditation, as core methods to teach awareness of negative thoughts and emotions with the aim of disengaging from pervasive patterns of ruminative self-centered mentation. Participants will be given an initial orientation session and then complete an online 8-week MBCT program. Each week participants will take part in one 2-hour online group session and will complete homework assignments anticipated to take 15-30 minutes per day to complete. Additionally, weekly phone coaching will be offered based on the modified tele-coach manual developed by Mohr and colleagues (Duffecy et al. 2010).
Study NCT04258241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration analgesia with local anesthetic
Description: The orthopedic surgeon will perform local infiltration analgesia at the end of the surgery. The knee joint capsule, periarticular and subcutaneous tissues will be infiltrated with 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline.
Study NCT04258241 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Local infiltration analgesia without local anesthetic
Description: The orthopedic surgeon will perform local infiltration analgesia at the end of the surgery. The knee joint capsule, periarticular and subcutaneous tissues will be infiltrated with 0.3 mg of epinephrine and 120 ml of normal saline.
Study NCT04258241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle
Description: 18-gauge 40 mm Sterican needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform local infiltration analgesia.
Study NCT04258241 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Needle
Description: 18-gauge 40 mm Sterican needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform local infiltration analgesia.
Study NCT03301012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recovery support as usual
Description: same as arm
Study NCT03301012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone assisted relapse prevention
Description: same as arm
Study NCT03301012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone assisted relapse prevention
Description: same as arm